Bullish Views for XPeng and Blueprint Medicines
- August 21st, 2023
- 445 views
XPeng Inc. (NYSE: XPEV), a leading Chinese electric vehicle manufacturer, received a boost in investor sentiment as BofA Securities upgraded the company from Neutral to Buy and raised the price target from $16.30 to $22.00.
Considering that $XPEV closed at $14.98 on Friday, the adjusted price target indicates a potential upside of $7.02 or approximately 46.83%, based on the financial advisory firm's assessment
In other news, Blueprint Medicines Corporation (Nasdaq: BPMC) continues to receive a favorable evaluation from Needham, as the brokerage firm maintained its Buy rating and raised the price target from $65 to $66.
Based on Friday's closing price of $49.29, the updated price target implies a potential upside of $16.71 or approximately 33.88% for $BPMC, according to Needham's analysis.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Treasury Targets Family Members and Associates of Maduro Regime
December 20th, 2025Herbal Works Inc. Supports President Trump's Order Easing Restriction on Cannabis
December 18th, 2025Herbal Works Inc. Plans on Expansion of Product Line in 2026
December 18th, 2025December 17th, 2025Crown Equity Holdings Inc. Announces Changes to Board of Directors
December 16th, 2025




Member Login